| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919345 | Radiotherapy and Oncology | 2013 | 5 Pages |
Abstract
The anti-proliferative activity of metformin may confer benefit in combination with radiotherapy, and this benefit is intensified upon loss of AMPK or p53 signaling.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hala Muaddi, Sanjana Chowdhury, Ravi Vellanki, Paul Zamiara, Marianne Koritzinsky,